Polico C, Saladini G, Casara D, Tomio L, Sotti G
Radiol Med. 1987 May;73(5):414-6.
The incidence of bone metastases in 448 patients with breast cancer was evaluated. 374 out of 448 cases showed negative bone scan at initial clinical staging and were followed up during a period of at least 5 years with serial bone scans. The results of bone scans were compared on the basis of clinical stage (according to the International UICC classification), of lymph node involvement (groups N0, N + ) and of complementary therapy after surgery (radiotherapy v/s hormone-chemotherapy). Cumulative probability of bone metastases in breast cancer showed a linear trend with annual mean rate of 5% (1st yr 2%; 2nd yr 8%; 3rd yr 15%; 4th yr 22%; 5th yr 29%; 10th yr 59%). Statistical analysis in different clinical stages showed mild difference not statistically significant, neither in lymph node involvement (NO v/s N + ) nor in complementary therapy (radiotherapy v/s hormone-chemotherapy).
评估了448例乳腺癌患者骨转移的发生率。448例病例中，374例在初始临床分期时骨扫描呈阴性，并在至少5年的时间里进行了系列骨扫描随访。根据临床分期（按照国际抗癌联盟UICC分类）、淋巴结受累情况（N0、N+组）以及术后辅助治疗（放疗与激素化疗）对骨扫描结果进行了比较。乳腺癌骨转移的累积概率呈线性趋势，年平均发生率为5%（第1年2%；第2年8%；第3年15%；第4年22%；第5年29%；第10年59%）。不同临床分期的统计分析显示差异轻微，在淋巴结受累情况（N0与N+）以及辅助治疗（放疗与激素化疗）方面均无统计学意义。
